Changes in Overall Health May Have Caused Recent Declines in Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis

THEODORE PINCUS, BENJAMIN ABELSON and TUULIKKI SOKKA

J Rheumatol 2010;37;1065
http://www.jrheum.org/content/37/5/1065.2

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Dr. Pincus et al, reply

To the Editor:

We appreciate Dr. Anderson’s interesting comments, and would offer the following:

1. The data presented did not involve a metaanalysis, but rather a compilation of reports that included data concerning mortality in patients with rheumatoid arthritis (RA) that included a baseline erythrocyte sedimentation rate (ESR). As noted in the report1, a computer search for “erythrocyte sedimentation rate (ESR)” and “rheumatoid arthritis (RA)” yielded about 86,000 reports. Even if it were possible to examine all these reports (which would require years), the results would likely have been similar to the reported data, which are consistent with clinical findings2-3.

2. ESR tests were performed according to the Westergren sedimentation rate, although in several reports the method was not mentioned. Nonetheless, the Wintrobe sedimentation rate, with a maximum of 100, yields lower values, and its use would have lowered the ESR in earlier studies, contrary to the findings.

3. Patients included in databases analyzed in this study were not participants in clinical trials, but rather in observational studies. This matter is relevant because inclusion criteria for clinical trials have remained relatively similar over the last 50 years, such as an ESR > 28 mm/h. Most patients with RA seen in our clinical settings did not meet inclusion criteria for current clinical trials4-5, in part as ESR was not > 28. In our opinion, the ESR requirement in clinical trials is undesirable, particularly as patients with normal and elevated ESR at baseline had a similar likelihood of taking methotrexate or biological agents (manuscript in preparation).

4. We would agree that the observation of lower levels of ESR may reflect nonspecifically milder inflammatory disease at this time compared to earlier periods. This phenomenon may meet a definition of an epiphenomenon, i.e., “an occurrence that is accidental, accessory, or incidental to a cause-and-effect relationship.” Nonetheless, there is no currently available measure of RA status, ranging from swollen joints to patient self-report scores for pain, that addresses a cause-and-effect relationship, and all clinical measures may be regarded as “epiphenomena.” All 7 RA Core Data Set measures are better that addresses a cause-and-effect relationship, and all clinical measures may be regarded as “epiphenomena.” All 7 RA Core Data Set measures are better.

5. The primary basis for any measure in clinical medicine is to provide guidance for clinical decisions. ESR is less likely to be abnormal than any of the other 6 Core Data Set measures for RA, including joint counts, questionnaire scores, and global measures, as noted in several recent poster presentations at the ACR and EULAR annual meetings. We recently recognized data from 4 additional sites from the early 1990s from the EURIDISS (European Research on Incapacitating Diseases and Social Support) study6, in which the mean ESR was < 30 mm/h in RA patients from Oslo (Norway), Nancy (France), Groningen (The Netherlands), and Belfast (Northern Ireland), now bringing to 7 the total number of locales with similar findings (Table 1).

We thank Dr. Anderson for his comments, and hope this correspondence will further alert rheumatologists to the likelihood of a normal ESR in a large fraction of patients with RA.

THEODORE PINCUS, MD; BENJAMIN ABELSON, BA, Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, 301 East 17th Street, Room 1608, New York, NY 10003, USA; TUULIKKI SOKKA, MD, PhD, Jyväskylä Central Hospital, Jyväskylä, Finland.

Address reprint requests to Dr. Pincus; E-mail: tedpincus@gmail.com

REFERENCES


5. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003;30:1138-46.


J Rheumatol 2010;37;5; doi:10.3899/jrheum.091361

Table 1. Erythrocyte sedimentation rate in 7 locations, 1980–2005.

<table>
<thead>
<tr>
<th>Location</th>
<th>n</th>
<th>Patients with ESR &lt; 28 mm/h, %</th>
<th>ESR (mm/h)</th>
<th>Mean</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wichita, KS, USA, 19942</td>
<td>1556</td>
<td>37% F, 45% M</td>
<td>37 F, 34 M</td>
<td>38 F</td>
<td>33 M</td>
</tr>
<tr>
<td>Oslo, Norway, 19966</td>
<td>237</td>
<td>—</td>
<td>26</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Nancy, France, 19966</td>
<td>135</td>
<td>29</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Groningen, The Netherlands, 19968</td>
<td>283</td>
<td>28</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Belfast, Northern Ireland, 19968</td>
<td>51</td>
<td>28</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Jyväskylä, Finland, 20093</td>
<td>1892</td>
<td>45%</td>
<td>—</td>
<td>30</td>
<td>—</td>
</tr>
<tr>
<td>Nashville, TN, USA, 20093</td>
<td>738</td>
<td>47%</td>
<td>—</td>
<td>30</td>
<td>—</td>
</tr>
</tbody>
</table>


5. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003;30:1138-46.


J Rheumatol 2010;37;5; doi:10.3899/jrheum.091361